Transplant
Conference Coverage
Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T
Awaiting CAR T therapy, patients with complete response to interim chemo show better outcomes with subsequent autologous transplantation, compared...
Conference Coverage
Hematology is in the Brodsky family’s blood
Three generations of Brodsky men have forged careers in the same medical field.
Conference Coverage
ASH 2023: Equity, Sickle Cell, and Real-Life Outcomes
Leaders of the American Society of Hematology preview hot topics and presentations on tap at their 2023 annual meeting.
Conference Coverage
More than one-third of adults in the US could have NAFLD by 2050
Findings suggest that health care systems should prepare for “large increases” in cases of hepatocellular carcinoma (HCC) and need for liver...
From the Journals
Trial shows utility of small-volume blood collection tubes
A clinical trial in Canada has found that small-volume blood collection tubes equal standard-volume tubes for specimen capture while reducing...
Conference Coverage
DLBCL treatment options: CAR T outperforms ASCT
Relapsed and refractory DLBCL patients treated with CAR T-cell therapy achieved better outcomes than with autologous stem cell transplants.
Conference Coverage
Frontline myeloma treatments: ASCT vs. CAR T
Experts debate whether CAR T-cell therapy could eventually replace autologous stem cell transplant (ASCT) as the standard of care for multiple...
Feature
Dispelling clinicians’ misconceptions about sickle cell disease
Among clinicians and their patients, widespread myths about sickle cell disease can stand in the way of adequate treatment.
News
FDA approves motixafortide for stem cell mobilization in myeloma
Motixafortide has been approved by the FDA to help mobilize hematopoietic stem cells in autologous transplants for patients with multiple myeloma...
Conference Coverage
Is additional treatment needed, pretransplant, for r/r AML?
The issue of whether or not patients with r/r AML require additional treatment pretransplant was debated at SOHO 2023.
From the Journals
Post-SCT, better survival in children with healthy gut diversity
After donor stem cell transplants, children with lower gut microbiota diversity show poorer survival and more complications.